Anastrozole vs DHB
FDA Approved vs Limited Research
compatible Researched · 90% Aromatase inhibitors are generally less necessary when DHB is part of a stack because DHB itself does not aromatize. AI requirements are determined entirely by the testosterone dose in the protocol. Some users find they can run a higher testosterone dose alongside DHB without needing as aggressive an AI approach as they would with other aromatizing compounds stacked on top of testosterone.
Molecular Data
Anastrozole DHB
Weight 293.37 Da 288.43 Da (base)
Half-life ~40-50 hours ~7-9 days (cypionate ester)
Type Nonsteroidal aromatase inhibitor (triazole derivative) 5-alpha reduced boldenone derivative (C19H28O2)
Key Benefits
Anastrozole
01 Potent reduction of circulating estradiol levels (70-80% at standard dose)
02 Prevents gynecomastia during testosterone or anabolic steroid cycles
03 Reduces estrogen-driven water retention and bloating
04 Helps control estrogen-related blood pressure elevation
05 Oral dosing with long half-life allows flexible scheduling (EOD or E3D)
06 Reversible inhibition allows estrogen recovery after discontinuation
07 Well-characterized pharmacokinetics with decades of clinical data
DHB
01 High anabolic potency (approximately 200:100 anabolic-to-androgenic ratio) promoting lean, quality muscle gains
02 No aromatization to estrogen, eliminating water retention, bloating, and gynecomastia risk from the compound itself
03 Produces dry, lean aesthetic gains comparable to Primobolan at a fraction of the cost
04 Does not convert to DHT or other more androgenic metabolites via 5-alpha reductase, as it is already 5-alpha reduced
05 Can be stacked with testosterone without significantly complicating estrogen management
06 Moderate androgenic activity supports strength gains without excessive androgenic side effects in most users
Dosing Protocols
Anastrozole
0.25-0.5mg EOD or E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
DHB
200-400 mg/week / 2-3x per week (cypionate)
Lean Bulk - Moderate 200-300 mg/week 2-3x per week (cypionate)
Lean Bulk - Standard 300-400 mg/week 2-3x per week (cypionate)
Cutting / Recomposition 200-300 mg/week 2-3x per week (cypionate)
Side Effects
Anastrozole
Joint pain, stiffness, or dryness (from reduced estrogen-mediated joint lubrication)
Hot flashes or flushing
Fatigue and general malaise
Mood changes (flat affect, irritability, or low mood)
Decreased libido (when estrogen is suppressed too aggressively)
Headache
DHB
Severe post-injection pain (PIP) -- the defining side effect of DHB, reported by the majority of users regardless of concentration, carrier oil, or injection technique. Pain typically begins 12-48 hours post-injection and can last 3-7 days, sometimes accompanied by redness, swelling, and warmth at the injection site.
Suppression of endogenous testosterone production (profoundly suppressive, as with all AAS)
Mild to moderate acne and oily skin in predisposed individuals
Mild hair thinning in genetically predisposed individuals
Mild liver stress (elevated ALT/AST reported even with injectable administration, potentially related to carrier solvents or the compound's metabolic pathway)
Contraindications
Known hypersensitivity to anastrozole or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with tamoxifen or estrogen-containing therapies
Hepatic impairment or liver disease (DHB has mild hepatotoxic potential)
Cardiovascular disease or history of thromboembolic events
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Known hypersensitivity to DHB, cypionate ester, or common carrier solvents (guaiacol, ethyl oleate)
Pregnancy or potential for pregnancy (Category X)
Pre-existing injection site complications or chronic inflammatory conditions at common injection sites
Research Evidence
Anastrozole DHB
Status FDA Approved Limited Research
References 5 studies 4 studies
Latest — January 2017
FDA Approved Yes No
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.